Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (61-70 of 174) with videos related to

Pageof 18
Sort By:
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsJames P Solomon, Irina Linkov, Andrea Rosado, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTGary A Ulaner, David M Hyman, Dara S Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, NeratinibGary A Ulaner, Cristina Saura, Sarina A Piha-Paul, et al.
The Journal of Molecular Diagnostics : JMD|December 29, 2016
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling AssayDara S Ross, Ahmet Zehir, Donavan T Cheng, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
Nature Medicine|May 12, 2026
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialLouis J Aronne, Deborah B Horn, Carel W le Roux, et al.
Blood Advances|March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester diseaseEli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
Pageof 18

Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
Cancer|December 6, 2011
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman, Qin Zhou, Alexia Iasonos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 4, 2019
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsJames P Solomon, Irina Linkov, Andrea Rosado, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 7, 2016
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CTGary A Ulaner, David M Hyman, Dara S Ross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, NeratinibGary A Ulaner, Cristina Saura, Sarina A Piha-Paul, et al.
The Journal of Molecular Diagnostics : JMD|December 29, 2016
Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling AssayDara S Ross, Ahmet Zehir, Donavan T Cheng, et al.
Neuro-Oncology|January 18, 2020
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient seriesAnkush Bhatia, Vaios Hatzoglou, Gary Ulaner, et al.
JAMA Oncology|June 7, 2018
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsRyan N Ptashkin, Diana L Mandelker, Catherine C Coombs, et al.
Nature Medicine|May 12, 2026
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialLouis J Aronne, Deborah B Horn, Carel W le Roux, et al.
Blood Advances|March 29, 2019
A scale for patient-reported symptom assessment for patients with Erdheim-Chester diseaseEli L Diamond, Anne S Reiner, Justin J Buthorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical SequencingMartee L Hensley, Shweta S Chavan, David B Solit, et al.
Pageof 18